Biotech Values

[DewDiligence]

ENTA—Interesting. If they got all those milestones, their cash level will more or less the same as their EV now.

That’s what I’ve been saying—see, for instance, #msg-89746606.

How much risk do you see on these trials?

The efficacy risk is de minimis—we already know from ABBV’s AVIATOR study that the ABT-450-based regimen works extremely well in genotype-1 patients. The only clinical risk of consequence is that the large number of patients being treated in the comprehensive phase-3 program will surface some newfound safety problem.